Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04711005
Recruitment Status : Recruiting
First Posted : January 15, 2021
Last Update Posted : February 2, 2021
Sponsor:
Information provided by (Responsible Party):
National Institute of Mental Health (NIMH)

Brief Summary:
A 6-cohort single ascending dose (SAD) study will be conducted in healthy volunteers utilizing a slow-infusion intravenous (IV) route of administration. Standard safety, pharmacokinetics (PK) and qEEG monitoring will be evaluated at all dose levels. Subsequently, a 3-cohort multiple ascending dose (MAD) study will be conducted. Doses will be administered on days 1, 4, 7, and 10. Standard safety parameters will be monitored, and PK will be evaluated at all dose levels.

Condition or disease Intervention/treatment Phase
Major Depressive Disorder Drug: (2R,6R)-Hydroxynorketamine hydrochloride Drug: Placebo Phase 1

Detailed Description:

A total of 48 Subjects are planned to be enrolled in a 6-cohort SAD study (36 in the treatment groups and 12 in the control groups). All SAD cohorts will have 6 Subjects in the treatment group and 2 Subjects in placebo group. All cohorts in the SAD study will incorporate sentinel dosing which will include 1 active and 1 placebo Subject. All remaining Subjects will be dosed at least 24 hours after the sentinel cohort participants. A total of 24 Subjects are planned to be enrolled in a 3 cohort MAD study (18 in the treatment groups and 6 in the control groups). All MAD cohorts will have 6 Subjects in the treatment group and 2 Subjects in placebo group.

(2R,6R)-Hydroxynorketamine hydrochloride will be administered intravenously over a 40-minute period as a solution in a 25 mM sodium phosphate 0.9% w/v saline solution. The SAD doses will range from 0.1 mg/kg to 4.0 mg/kg and the investigational drug product will be diluted into a 53 mL total volume of formulant. Placebo will be made up of a 0.9% w/v saline solution (53 mL total volume) also administered via slow IV infusion over a 40-minute period.

Serial PK blood samples will be collected during the SAD portion for each Subject receiving drug and placebo at 9 timepoints (preinfusion, end-of-infusion [approximately 40 minutes], 1, 2, 4, 8, 12, 24, and approximately 48 hr after the start of the infusion). Pharmacokinetic urine samples will be collected during the SAD study for each Subject receiving drug and placebo at set intervals following the initiation-of-infusion (0-4, >4-8, >8-12, >12-24 hr). Serial PK blood and urine samples will be collected for the first and fourth (last) dosing in the MAD study for each Subject receiving drug and placebo. Blood PK samples will be obtained at 9 timepoints (preinfusion, end-of-infusion [approximately 40 minutes], 1, 2, 4, 8, 12, 24, and approximately 48 hr after the start of the infusion). A single PK blood sample will be collected for the second and third dosing in the MAD study for each Subject receiving drug and placebo at approximately 10 minutes predose. Pharmacokinetic urine samples will be collected during the MAD study for each Subject receiving drug and placebo at set intervals following the initiation-of-infusion (0-4, >4-8, >8-12, >12-24 hr) after the first and last dose.

Safety will be assessed throughout the study. Baseline and follow-up safety assessments will include height, body mass index (BMI), weight, temperature, medical, visual and ocular history, physical examinations, ocular examinations, visual acuity, color vision tests, electrocardiograms (ECGs), vital signs (VS), clinical laboratory tests (hematology, serum chemistry, and urinalysis), the Profile of Mood States (POMS), the Columbia-Suicide Severity Rating Scale (C-SSRS), the Clinician Administered Dissociative States Scale (CADSS), and adverse events (AEs). Safety assessments will include AEs, ECGs, VS, clinical laboratory results, and physical observations. Assessment of each Subject's level of alertness/sedation will be accomplished using the Modified Observer's Assessment of Alertness/Sedation (MOAA/S). Evaluation of safety in the MAD study will utilize the same safety assessments used in the SAD study. Monitoring of AEs will be governed by change from baselines established during prescreening and Day -1 examinations and clinical laboratory tests. Dose escalation in the SAD study or continued dosing in the MAD study may be stopped according to the predefined halting rules or if a Subject's scores demonstrate acute suicidality on the C-SSRS assessment or at the discretion of the study Principal Investigator and/or sponsor. Determination of whether to escalate to the next dose level in the SAD study or continue dosing in the MAD will be made by the Principal Investigator in consultation with the Medical Monitor and Study Sponsor.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: A 6-cohort single ascending dose (SAD) study will be conducted in healthy volunteers followed by a 3-cohort multiple ascending dose (MAD) study in healthy volunteers.
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Double-Blind, Placebo-controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study of the Safety, Pharmacokinetics and Pharmacodynamics of (2R,6R)-Hydroxynorketamine in Healthy Volunteers
Actual Study Start Date : January 11, 2021
Estimated Primary Completion Date : November 2021
Estimated Study Completion Date : November 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: SAD Cohort 1
(2R,6R)-Hydroxynorketamine @ 0.1 mg/kg via slow IV infusion (40 minutes)
Drug: (2R,6R)-Hydroxynorketamine hydrochloride
(2R,6R)-Hydroxynorketamine is a metabolite of the drug ketamine. (2R,6R)-Hydroxynorketamine hydrochloride will be administered intravenously over a 40-minute period as a solution in a 25 mM sodium phosphate 0.9% w/v saline solution. The investigational drug product will be diluted into a 53 mL total volume of formulant.

Experimental: SAD Cohort 2
(2R,6R)-Hydroxynorketamine @ 0.25 mg/kg via slow IV infusion (40 minutes)
Drug: (2R,6R)-Hydroxynorketamine hydrochloride
(2R,6R)-Hydroxynorketamine is a metabolite of the drug ketamine. (2R,6R)-Hydroxynorketamine hydrochloride will be administered intravenously over a 40-minute period as a solution in a 25 mM sodium phosphate 0.9% w/v saline solution. The investigational drug product will be diluted into a 53 mL total volume of formulant.

Experimental: SAD Cohort 3
(2R,6R)-Hydroxynorketamine @ 0.5 mg/kg via slow IV infusion (40 minutes)
Drug: (2R,6R)-Hydroxynorketamine hydrochloride
(2R,6R)-Hydroxynorketamine is a metabolite of the drug ketamine. (2R,6R)-Hydroxynorketamine hydrochloride will be administered intravenously over a 40-minute period as a solution in a 25 mM sodium phosphate 0.9% w/v saline solution. The investigational drug product will be diluted into a 53 mL total volume of formulant.

Experimental: SAD Cohort 4
(2R,6R)-Hydroxynorketamine @ 1.0 mg/kg via slow IV infusion (40 minutes)
Drug: (2R,6R)-Hydroxynorketamine hydrochloride
(2R,6R)-Hydroxynorketamine is a metabolite of the drug ketamine. (2R,6R)-Hydroxynorketamine hydrochloride will be administered intravenously over a 40-minute period as a solution in a 25 mM sodium phosphate 0.9% w/v saline solution. The investigational drug product will be diluted into a 53 mL total volume of formulant.

Experimental: SAD Cohort 5
(2R,6R)-Hydroxynorketamine @ 2.0 mg/kg via slow IV infusion (40 minutes)
Drug: (2R,6R)-Hydroxynorketamine hydrochloride
(2R,6R)-Hydroxynorketamine is a metabolite of the drug ketamine. (2R,6R)-Hydroxynorketamine hydrochloride will be administered intravenously over a 40-minute period as a solution in a 25 mM sodium phosphate 0.9% w/v saline solution. The investigational drug product will be diluted into a 53 mL total volume of formulant.

Experimental: SAD Cohort 6
(2R,6R)-Hydroxynorketamine @ 4.0 mg/kg via slow IV infusion (40 minutes)
Drug: (2R,6R)-Hydroxynorketamine hydrochloride
(2R,6R)-Hydroxynorketamine is a metabolite of the drug ketamine. (2R,6R)-Hydroxynorketamine hydrochloride will be administered intravenously over a 40-minute period as a solution in a 25 mM sodium phosphate 0.9% w/v saline solution. The investigational drug product will be diluted into a 53 mL total volume of formulant.

Experimental: MAD Cohort 1
(2R,6R)-Hydroxynorketamine @ 0.5 mg/kg via slow IV infusion (40 minutes) on days 1, 4, 7, 10
Drug: (2R,6R)-Hydroxynorketamine hydrochloride
(2R,6R)-Hydroxynorketamine is a metabolite of the drug ketamine. (2R,6R)-Hydroxynorketamine hydrochloride will be administered intravenously over a 40-minute period as a solution in a 25 mM sodium phosphate 0.9% w/v saline solution. The investigational drug product will be diluted into a 53 mL total volume of formulant.

Experimental: MAD Cohort 2
(2R,6R)-Hydroxynorketamine @ 1.0 mg/kg via slow IV infusion (40 minutes) on days 1, 4, 7, 10
Drug: (2R,6R)-Hydroxynorketamine hydrochloride
(2R,6R)-Hydroxynorketamine is a metabolite of the drug ketamine. (2R,6R)-Hydroxynorketamine hydrochloride will be administered intravenously over a 40-minute period as a solution in a 25 mM sodium phosphate 0.9% w/v saline solution. The investigational drug product will be diluted into a 53 mL total volume of formulant.

Experimental: MAD Cohort 3
(2R,6R)-Hydroxynorketamine @ 2.0 mg/kg via slow IV infusion (40 minutes) on days 1, 4, 7, 10
Drug: (2R,6R)-Hydroxynorketamine hydrochloride
(2R,6R)-Hydroxynorketamine is a metabolite of the drug ketamine. (2R,6R)-Hydroxynorketamine hydrochloride will be administered intravenously over a 40-minute period as a solution in a 25 mM sodium phosphate 0.9% w/v saline solution. The investigational drug product will be diluted into a 53 mL total volume of formulant.

Placebo Comparator: Placebo
Control product (placebo) will be sterile saline also administered via slow IV infusion (40 minutes).
Drug: Placebo
Placebo will be made up of a 0.9% w/v saline solution (53 mL total volume) administered via slow IV infusion over a 40-minute period.




Primary Outcome Measures :
  1. Number of subjects with adverse events as a measure of safety and tolerability of (2R,6R)-Hydroxynorketamine [ Time Frame: 8 days post dosing (SAD) ]
    Investigational product-related adverse events and serious adverse events

  2. Number of subjects with adverse events as a measure of safety and tolerability of (2R,6R)-Hydroxynorketamine [ Time Frame: 19 days post dosing (MAD) ]
    Investigational product-related adverse events and serious adverse events

  3. Number of subjects with adverse events as a measure of safety and tolerability of (2R,6R)-Hydroxynorketamine [ Time Frame: 8 days post dosing (SAD) ]
    Vital signs (systolic and diastolic blood pressure, pulse rate, respiration, temperature)

  4. Number of subjects with adverse events as a measure of safety and tolerability of (2R,6R)-Hydroxynorketamine [ Time Frame: 19 days post dosing (MAD) ]
    Vital signs (systolic and diastolic blood pressure, pulse rate, respiration, temperature)

  5. Number of subjects with adverse events as a measure of safety and tolerability of (2R,6R)-Hydroxynorketamine [ Time Frame: 8 days post dosing (SAD) ]
    12 lead electrocardiogram including heart rate, rhythm, RR interval, QT interval, QTcF interval, PR interval, and QRS duration

  6. Number of subjects with adverse events as a measure of safety and tolerability of (2R,6R)-Hydroxynorketamine [ Time Frame: 19 days post dosing (MAD) ]
    12 lead electrocardiogram including heart rate, rhythm, RR interval, QT interval, QTcF interval, PR interval, and QRS duration

  7. Number of subjects with adverse events as a measure of safety and tolerability of (2R,6R)-Hydroxynorketamine [ Time Frame: 8 days post dosing (SAD) ]
    Clinical laboratory assessments (serum chemistry, hematology, urinalysis)

  8. Number of subjects with adverse events as a measure of safety and tolerability of (2R,6R)-Hydroxynorketamine [ Time Frame: 19 days post dosing (MAD) ]
    Clinical laboratory assessments (serum chemistry, hematology, urinalysis)

  9. Pharmacokinetics of (2R,6R)-Hydroxynorketamine, maximum plasma concentration (Cmax) [ Time Frame: 3 days post dosing (SAD), 12 days post dosing (MAD) ]
    This parameter will be calculated as appropriate and if possible for (2R,6R)-Hydroxynorketamine, depending on actual samples collected.

  10. Pharmacokinetics of (2R,6R)-Hydroxynorketamine, time taken to reach maximum plasma concentration (tmax) [ Time Frame: 3 days post dosing (SAD), 12 days post dosing (MAD) ]
    This parameter will be calculated as appropriate and if possible for (2R,6R)-Hydroxynorketamine, depending on actual samples collected.

  11. Pharmacokinetics of (2R,6R)-Hydroxynorketamine, minimum plasma concentration at the end of the dosing interval after each dose in the MAD study (Cmin) [ Time Frame: 12 days post dosing (MAD) ]
    This parameter will be calculated as appropriate and if possible for (2R,6R)-Hydroxynorketamine, depending on actual samples collected.

  12. Pharmacokinetics of (2R,6R)-Hydroxynorketamine, area under the curve concentration (AUC) [ Time Frame: 3 days post dosing (SAD), 12 days post dosing (MAD) ]
    This parameter will be calculated as appropriate and if possible for (2R,6R)-Hydroxynorketamine, depending on actual samples collected.

  13. Pharmacokinetics of (2R,6R)-Hydroxynorketamine, plasma drug clearance (CL) [ Time Frame: 3 days post dosing (SAD), 12 days post dosing (MAD) ]
    This parameter will be calculated as appropriate and if possible for (2R,6R)-Hydroxynorketamine, depending on actual samples collected.

  14. Pharmacokinetics of (2R,6R)-Hydroxynorketamine, renal drug clearance (CLr) [ Time Frame: 3 days post dosing (SAD), 12 days post dosing (MAD) ]
    This parameter will be calculated as appropriate and if possible for (2R,6R)-Hydroxynorketamine, depending on actual samples collected.

  15. Pharmacokinetics of (2R,6R)-Hydroxynorketamine, apparent volume of distribution during terminal phase (Vz) [ Time Frame: 3 days post dosing (SAD), 12 days post dosing (MAD) ]
    This parameter will be calculated as appropriate and if possible for (2R,6R)-Hydroxynorketamine, depending on actual samples collected.

  16. Pharmacokinetics of (2R,6R)-Hydroxynorketamine, half-life (t1/2) [ Time Frame: 3 days post dosing (SAD), 12 days post dosing (MAD) ]
    This parameter will be calculated as appropriate and if possible for (2R,6R)-Hydroxynorketamine, depending on actual samples collected.


Secondary Outcome Measures :
  1. Pharmacodynamics of (2R,6R)-Hydroxynorketamine, quantitative electroencephalography (qEEG) relative spectral power [ Time Frame: 3 hours post dosing (SAD) ]
    An FFT analysis will be performed on the raw EEG. From this FFT analysis, the absolute and relative power spectrum will be determined across all frequency bands (delta, theta, alpha, beta and gamma).

  2. Pharmacodynamics of (2R,6R)-Hydroxynorketamine, quantitative electroencephalography (qEEG) visual evoked time-locked data [ Time Frame: 3 hours post dosing (SAD) ]
    Analysis of sensory processing will be conducted through consideration of the visual evoked potential to a contrast reversing checkerboard.

  3. Pharmacodynamics of (2R,6R)-Hydroxynorketamine, quantitative electroencephalography (qEEG) source localization [ Time Frame: 3 hours post dosing (SAD) ]
    Frequency-specific and time-locked source localization will be performed using sLORETA within regions-of-interest specifying Default Mode, Central Executive, and Somatosensory networks.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Be a healthy male or female between 18 and 65 years of age (inclusive).
  2. Voluntarily consents to participate in the study and provides written informed consent before the start of any study-specific procedures.
  3. Be willing and able to remain in the study unit for the entire duration of the confinement period and return for outpatient visits.
  4. Agree to comply with prohibitions and restrictions (section 8.5).
  5. Females must have a negative serum β-human chorionic gonadotropin (hCG) pregnancy test at screening and a negative urine pregnancy test on Day -1 prior to study initiation.
  6. Females must be of nonchildbearing potential or agree to use appropriate birth control, as defined in section 8.4 Contraception Requirements.
  7. Males must be surgically sterile for at least 90 days before screening or agree to use a condom with spermicide when sexually active with a female partner who is not using an acceptable form of birth control during the study and for 90 days after study administration. Males must also agree to not donate sperm starting at enrollment and for 90 days after last study drug administration.
  8. BMI (weight [kg]/[m2]) between 18 and 35 kg/m2 (inclusive) and weighs between 50 and 120 kg (110 - 264 pounds), inclusive.
  9. Blood pressure (after Subject is in a supine position for approximately 5 minutes) between 90 and 145 mmHg systolic (inclusive) and no higher than 90 mmHg diastolic at Screening and Day -1.
  10. A 12-lead ECG with no clinically significant abnormality as judged by the Investigator and QTc interval ≤ 450 milliseconds at Screening and Day -1.
  11. Resting pulse rate between 45 and 100 beats per minute at Screening and Day -1.
  12. Clinical laboratory findings and VS within normal range, or if outside of the normal ranges, deemed not clinically significant in the opinion of the Investigator.
  13. Agree to comply with the rules regarding consumption of alcohol, caffeinated beverages, and tobacco/nicotine products during the study.

Exclusion Criteria:

  1. History or presence of clinically significant medical illness including (but not limited to) hepatic, cardiovascular, pulmonary, renal, hematologic, endocrine, gastrointestinal, immunologic, dermatologic, neurologic, oncologic, or psychiatric disease that in the opinion of the Investigator would endanger the safety of the Subject or the validity of the study results.
  2. Clinically significant acute illness in the 2 weeks prior to dosing.
  3. Previous or current participation in any clinical study with an investigational drug, device, or biologic within 30 days or five half-lives of the investigational product to dosing.
  4. Preplanned surgery or procedures that would interfere with the conduct of the study.
  5. History of severe drug or excipient allergy, or hypersensitivity to be judged at the discretion of the Investigator.
  6. Donation or loss of greater than 0.5 L of blood within 90 days before screening or study start. Donation of platelets within 40 days before screening or study start. Donation of plasma within 14 days before screening or study start. Receipt of blood products within 60 days before screening or study start.
  7. Recent history (2 years) of alcohol or drug abuse at the discretion of the Investigator or a positive screen for alcohol or drugs of abuse (including marijuana) at screening and upon check-in.
  8. Testing positive for hepatitis B, hepatitis C, or HIV, or a history of any of these diseases. Subjects whose results are compatible with prior immunization may be included at the discretion of the Investigator.
  9. History of unexplained loss of consciousness, epilepsy, or other seizure disorders, or cerebrovascular disease.
  10. Malignancy within 5 years of screening visit (except basal cell or squamous cell skin carcinoma).
  11. Inability to adhere to the study unit diet.
  12. Use of any prescription or nonprescription medication (including vitamins, herbal preparations, and nutritional supplements) within the 14 days prior to dosing except for common analgesics (acetaminophen, ibuprofen), hormonal contraceptives or hormonal replacement therapy or nonsedating antihistamines. Topical medications may be allowed at the discretion of the Investigator.
  13. History or current diagnosis of mental illness including (but not limited to) psychotic disorder, bipolar disorder, schizophrenia, borderline personality disorder, and antisocial personality disorder, generalized anxiety disorder, obsessive compulsive disorder, posttraumatic stress disorder, and eating disorders.
  14. History of suicidal or homicidal ideation.
  15. Significant primary sleep disorder.
  16. Known allergy to ketamine, heparin, or any of the IDP components (see section 10.0 Study Drug Information).
  17. Any strenuous exercise in the 2 days prior to study drug administration.
  18. Consumption of beverages or food that contain alcohol, grapefruit, poppy seeds, Brussel sprouts, pomegranate, broccoli, char-grilled meat within 2 days prior to drug administration. Allowances for a single isolated incidental consumption may be evaluated and approved pending PI approval for the potential interactions.
  19. Use of tobacco or nicotine-containing products within 4 weeks prior to drug administration.
  20. Employee of the PI or study center with direct involvement in the proposed study or other studies under the direction of the study PI.
  21. Poor peripheral venous access.
  22. Close relative (parent, sibling, child) of clinical site employee.
  23. Subjects who, in the opinion of the PI or designee, should not participate in this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04711005


Contacts
Layout table for location contacts
Contact: Lynn Jordan 919-613-0952 lynn.jordan@duke.edu

Locations
Layout table for location information
United States, North Carolina
Duke Early Phase Clinical Research Recruiting
Durham, North Carolina, United States, 27710
Contact: Sarah Oxendine    919-668-0926    sarah.oxendine@duke.edu   
Principal Investigator: Jeffrey Guptill, MD         
Sponsors and Collaborators
National Institute of Mental Health (NIMH)
  Study Documents (Full-Text)

Documents provided by National Institute of Mental Health (NIMH):
Informed Consent Form  [PDF] December 2, 2020

Layout table for additonal information
Responsible Party: National Institute of Mental Health (NIMH)
ClinicalTrials.gov Identifier: NCT04711005    
Other Study ID Numbers: HNK-378227-01
18-01 ( Other Identifier: National Center for Advancing Translational Sciences (NCATS) )
First Posted: January 15, 2021    Key Record Dates
Last Update Posted: February 2, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by National Institute of Mental Health (NIMH):
Healthy Volunteers
Depression
Antidepressant
Additional relevant MeSH terms:
Layout table for MeSH terms
Depressive Disorder
Depressive Disorder, Major
Mood Disorders
Mental Disorders